Illumina Expands Product Portfolio to Support Oncology Clinical Research and Discovery

  Illumina Expands Product Portfolio to Support Oncology Clinical Research and
  Discovery

     End-to-End Genomics Solutions Will Transform the Future of Oncology

Business Wire

SAN DIEGO -- April 2, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced new products that can be applied
directly to the discovery and translation of genomic variation in blood and
tissue associated with cancer. The expanded portfolio leverages the company’s
industry-leading next-generation sequencing (NGS) and microarray scanning
systems to deliver sample-to-data solutions for basic and clinical cancer
research.

New Product Additions

The following products complement the company’s existing NGS and array
portfolio and support efficient and streamlined workflows for cancer research
and other applications using Illumina’s NGS sequencers, including the newly
launched NextSeq™ 500 sequencing system.

  *TruSeq® RNA Access Library Prep Kits offer a reproducible, economical
    solution for analyzing RNA isolated from formalin-fixed, paraffin-embedded
    (FFPE) tissues, and other low-quality samples. Starting with as little as
    10 ng total RNA, the kits deliver the discovery power of RNA sequencing at
    a reduced cost by focusing on the coding regions of the transcriptome. The
    kits will begin shipping this month. In addition, the kits will be
    available on the NeoPrep^TM Library Prep System in 2H 2014.
  *TruSight™ Myeloid Sequencing Panel uses expert-curated content to offer
    accurate, efficient, and cost-effective identification of somatic
    mutations in myeloid malignancies. It provides an assessment of 54
    critical genes, including tumor suppressor genes and hotspots in
    oncogenes. This fully integrated DNA-to-data solution offers a streamlined
    workflow and automated data analysis with somatic variant calling. The
    panel will begin shipping in Q2 2014.
  *New BaseSpace® Core Apps  offer informatics support for the cancer market.
    The TopHat and Cufflinks Apps, as well as the RNA Express App, are
    designed to support transcriptome data analysis, including detection of
    fusion genes critical in cancer research. A Tumor Normal App delivers
    somatic variant calling of tumor and matched normal whole genome data sets
    based on the accurate Strelka method. In addition, Illumina is developing
    apps to analyze data from Illumina’s TruSight Tumor Sequencing Panel and
    TruSeq Amplicon - Cancer Panel, as well as an exome version of the Tumor
    Normal App that delivers variants (including copy number variations) based
    on Nextera® Rapid Capture Enrichment data. The RNA-Seq and Tumor Normal
    Apps will be available early this month in BaseSpace, and the others will
    be available later in 2014.

“The adoption of a precision cancer medicine, a clinical paradigm based on
genetic assessment of a patient’s cancer, is rapidly occurring,” said Hanlee
Ji, an Assistant Professor of Medicine at Stanford University and Senior
Associate Director of the Stanford Genome Technology Center. “As a
physician-scientist who is actively developing and applying novel sequencing
approaches in the clinical oncology setting, Illumina’s NGS systems are
instrumental tools. The advances in NGS with improved sequence quality and
dramatic reduction in cost will continue to enable progress in oncology and
genomic medicine.”

“The latest additions to our product portfolio address the unique needs of
oncology researchers,” said Rick Klausner, M.D., Chief Medical Officer of
Illumina. “Our product solutions now support library preparation of the
low-input, poor-quality archival tissue samples that are so valuable for
cancer research. We’re accelerating the discovery of cancer-associated
variants with simple-to-use data analysis solutions, including software tools
that support the creation of genotypic/phenotypic databases. Our goal is to
expand the use of NGS beyond basic research, delivering relevant oncological
genomic information to clinical researchers where it has the potential to
inform improvements in cancer care.”

For more information about Illumina’s oncology portfolio, visit
www.illumina.com/cancersolutions.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected availability and
shipping dates for new products and services. Important factors that could
cause actual results to differ materially from those in any forward-looking
statements include challenges inherent in developing, manufacturing, and
launching new products and services and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.